Taysha Gene Therapies (TSHA) Research & Development (2020 - 2026)

Taysha Gene Therapies has reported Research & Development for 7 years, with the latest figure at $33.8 million in Q1 2026.

• Quarterly Research & Development rose 117.21% year-over-year to $33.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (up 619.16% YoY) and the FY2025 annual result came in at $3.0 million, up 200.0% from the prior year.
• Research & Development grew to $33.8 million in Q1 2026 per TSHA's latest filing, from -$58.5 million in the prior quarter.
• Over five years, Research & Development peaked at $38.2 million in Q1 2022 and troughed at -$58.5 million in Q4 2025.
• A 5-year average of $7.8 million and a median of $15.6 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2026: Research & Development tumbled 419.48% in 2023, then jumped 117.21% in 2026.
• Over 5 years, Research & Development stood at $12.7 million in 2022, then sank by 419.48% to -$40.6 million in 2023, then retreated by 22.37% to -$49.7 million in 2024, then retreated by 17.66% to -$58.5 million in 2025, then soared by 157.84% to $33.8 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $33.8 million, -$58.5 million, and $25.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.